ClinicalTrials.gg
CompletedNCT05375838Updated Feb 28, 2024Results posted

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

A Phase 1/2 interventional study of mRNA-1073 and mRNA-1010 in SARS-CoV-2 and Influenza, sponsored by ModernaTX, Inc.. Completed at 14 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human — 2 open to participants now, 2 under way, none of them phase 3. mRNA-1010 influenza vaccine · Influenza, Human.

Enrollment
6th of 12
550 · median 471
Started
2022
with 5 others
Phase 1/2
2 of 12
none open now
Registered
2nd of 12
by date
Lead sponsor
12 of 12
ModernaTX, Inc.

Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, this one is the 6th largest by enrollment, is one of 6 that started in 2022, is one of 2 in phase 1/2, and was the 2nd registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About mRNA-1010 influenza vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, or all of them as a file.
02

Study summary

The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants.

03

Conditions studied

  • SARS-CoV-2
  • Influenza

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of 18 kilograms per meter squared (kg/m\^2) to 35 kg/m\^2 (inclusive) at the Screening Visit.
  • Participants must have been fully vaccinated for COVID-19 primary series according to the locally authorized or approved regimen, and their last COVID-19 vaccine (primary series or booster) was ≥ 120 days prior to the randomization visit (or less per local guidance).

Exclusion criteria

Exclusion Criteria:

  • Participant is acutely ill or febrile (temperature ≥ 38.0℃ [100.4°F]) 72 hours prior to or at the Screening Visit or Day 1. Participants meeting this criterion may be rescheduled within the 28-day Screening window and will retain their initially assigned participant number.
  • Participant has a history of a diagnosis or condition that, in the judgment of the investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures. Clinically unstable is defined as a diagnosis or condition requiring significant changes in management or medication ≤ 60 days prior to Screening and includes ongoing workup of an undiagnosed illness that could lead to a new diagnosis or condition. Asymptomatic conditions and conditions with no evidence of end organ involvement (for example, mild hypertension, dyslipidemia) are not exclusionary, provided that they are being appropriately managed and are clinically stable (for example, unlikely to result in symptomatic illness within the time course of this study). Illnesses or conditions may be exclusionary, even if otherwise stable, due to therapies used to treat them (for example, immune-modifying treatments), at the discretion of the investigator.
  • Participant has a reported history of congenital or acquired immunodeficiency, condition, or immune-mediated disease.
  • Participant has dermatologic conditions that could affect local solicited adverse reaction (AR) assessments (for example, tattoos, psoriasis patches affecting skin over the deltoid areas).
  • Participant has a reported history of anaphylaxis or severe reaction after receipt of any mRNA vaccine(s) or any components of the mRNA vaccines.
  • Participant has a reported history of bleeding disorder that is considered a to IM injection or phlebotomy.
  • Participant has a diagnosis of within previous 10 years (excluding nonmelanoma skin cancer).
  • Participant has any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
  • Participant has received systemic immunosuppressants or immune-modifying drugs for > 14 days in total within 6 months prior to Screening (for ≥ 10 mg/day of prednisone or equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study. Inhaled, nasal, topical steroids are not exclusionary.
  • Participant has received or plans to receive any vaccine authorized or approved by a local health agency ≤ 28 days prior to study injections (Day 1) or plans to receive a vaccine authorized or approved by a local health agency within 28 days before or after the study injections.
  • Participant has received a seasonal influenza vaccine or any other influenza vaccine ≤ 180 days prior to the randomization visit.
  • Participant has tested positive for influenza by local health authority approved testing methods ≤ 180 days prior to the Screening Visit.
  • Participant has had close contact to someone with SARS-CoV-2 infection or COVID-19 as defined by the US CDC in the past 10 days prior to the Screening Visit.
  • Participant has known history of SARS-CoV-2 infection within ≤ 90 days.
  • Participant has received systemic immunoglobulins or blood products ≤ 90 days prior to the Screening Visit or plans to receive systemic immunoglobulins or blood products during the study.
  • Participant has a history of myocarditis, pericarditis, or myopericarditis.
  • Participant has donated ≥ 450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products during the study.
  • Participated in an interventional clinical study within 28 days prior to the Screening Visit based on the medical history interview or plans to do so while participating in this study.
  • Participant is an immediate family member or household member of study personnel, study site staff, or Sponsor personnel.

Phase 1 Specific Exclusion Criteria:

  • Participant has clinical screening laboratory values (total white blood cell count, , , (ALT), aspartate aminotransferase (AST), creatinine, alkaline phosphatase, and total ) > Grade 1.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
550 participants (actual)

Study arms

  • Experimental
    mRNA-1273 Plus Placebo

    Participants will receive 2 intramuscular (IM) injections, one in each arm, of mRNA-1273 plus placebo at the specified dose level on Day 1.

    Biological: mRNA-1273 · Biological: Placebo

  • Experimental
    mRNA-1010 Plus Placebo

    Participants will receive 2 IM injections, one in each arm, of mRNA-1010 plus placebo at the specified dose level on Day 1.

    Biological: mRNA-1010 · Biological: Placebo

  • Experimental
    mRNA-1010 Plus mRNA-1273

    Participants will receive 2 IM injections, one in each arm, of mRNA-1010 plus mRNA-1273 at the specified dose level on Day 1.

    Biological: mRNA-1010

  • Experimental
    Dose A: mRNA-1073 Plus Placebo

    Participants will receive 2 IM injections, one in each arm, of mRNA-1073 plus placebo at the specified dose level on Day 1.

    Biological: mRNA-1073 · Biological: Placebo

  • Experimental
    Dose B: mRNA-1073 Plus Placebo

    Participants will receive 2 IM injections, one in each arm, of mRNA-1073 plus placebo at the specified dose level on Day 1.

    Biological: mRNA-1073 · Biological: Placebo

  • Experimental
    Dose C: mRNA-1073 Plus Placebo

    Participants will receive 2 IM injections, one in each arm, of mRNA-1073 plus placebo at the specified dose level on Day 1.

    Biological: mRNA-1073 · Biological: Placebo

Interventions

  • BiologicalmRNA-1073

    Sterile liquid for injection

  • BiologicalmRNA-1010

    Sterile liquid for injection

  • BiologicalmRNA-1273

    Sterile liquid for injection

  • BiologicalPlacebo

    0.9% sodium chloride (normal saline) injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Solicited Local and Systemic Adverse Reaction (ARs)

    Solicited ARs (local and systemic) were collected in the electronic diary (eDiary). Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. Note, that not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of all serious AEs (SAEs) and all nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section.

    Time frame: Up to Day 8 (7 days post vaccination)

  2. Number of Participants With Unsolicited Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A treatment-emergent AE (TEAE) was defined as any event not present before exposure to vaccine or any event already present that worsens in intensity or frequency after exposure. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsens from baseline and is considered clinically significant in the medical and scientific judgment of the Investigator. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study, regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Up to Day 29 (28 days post vaccination)

  3. Number of Participants With Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), Medically-Attended AEs (MAAEs) and AEs Leading to Discontinuation

    An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner. This would include visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or COVID-19 and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Up to Day 181

Secondary outcomes

  1. Geometric Mean Titer of Anti-Hemagglutinin Antibodies at Day 29, as Measured by Hemagglutination Inhibition Assay (HAI) For Vaccine-Matched Seasonal Influenza A and B Strains

    Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included BV and BY.

    Time frame: Day 29

  2. Geometric Mean Titer of VAC62 Neutralizing Antibody at Day 29, as Measured by Pseudovirus Neutralization Assay (or Binding Antibody Assay) For Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

    Time frame: Day 29

  3. Geometric Mean Fold Rise of Anti-Hemagglutinin Antibodies at Day 29, as Measured by Hemagglutination Inhibition Assay (HAI) For Vaccine-Matched Seasonal Influenza A and B Strains

    Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included BV and BY.

    Time frame: Day 29

  4. Geometric Mean Fold Rise of VAC62 Neutralizing Antibody at Day 29, as Measured by Pseudovirus Neutralization Assay (or Binding Antibody Assay) For SARS-CoV-2

    The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. 95% CI was calculated based on the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation.

    Time frame: Day 29

  5. Percentage of Participants With Seroconversion as Measured by HAI Assay For Vaccine-Matched Seasonal Influenza A and B Strains

    Seroconversion at a participant level is defined as a pre-vaccination HAI titer \< 1:10 and a post-vaccination HAI titer \>= 1:40 or a pre-vaccination HAI titer \>= 1:10 and a minimum 4-fold rise in post vaccination HAI antibody titer.

    Time frame: Day 29

  6. Percentage of Participants With Seroresponse as Measured by PsVNA (or Binding Antibody Assay) For SARS-CoV-2

    Seroresponse at a participant level is defined as an increase from below the lower limit of quantification (LLOQ) to \>= 4 x LLOQ if baseline neutralizing antibody (nAb) level is \< LLOQ, or \>= 4 fold rise if baseline nAb level is \>=LLOQ.

    Time frame: Day 29

07

Results

Posted Feb 28, 2024

Participant flow

Participant flow — Overall Study
MilestonemRNA-1273 + PlacebomRNA-1010 + PlacebomRNA-1010 + mRNA-1273Dose A: mRNA-1073 Low Dose + PlaceboDose B: mRNA-1073 Medium Dose + PlaceboDose C: mRNA-1073 High Dose + Placebo
Started5099101100100100
Received at least 1 dose of study drug499910110098100
Completed469098939496
Not completed493764
Withdrew: Other000110
Withdrew: Withdrawal by subject213220
Withdrew: Protocol violation000010
Withdrew: Physician decision010001
Withdrew: Lost to follow-up270423

Outcome measures

PrimaryNumber of Participants With Solicited Local and Systemic Adverse Reaction (ARs)

Solicited ARs (local and systemic) were collected in the electronic diary (eDiary). Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. Note, that not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of all serious AEs (SAEs) and all nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section.

Time frame:
Up to Day 8 (7 days post vaccination)
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local and Systemic Adverse Reaction (ARs)
ParticipantsmRNA-1273 + PlacebomRNA-1010 + PlacebomRNA-1010 + mRNA-1273Dose A: mRNA-1073 Low Dose + PlaceboDose B: mRNA-1073 Medium Dose + PlaceboDose C: mRNA-1073 High Dose + Placebo
Solicited Local ARs388090927678
Solicited Systemic ARs317087806367
PrimaryNumber of Participants With Unsolicited Adverse Events (AEs)

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A treatment-emergent AE (TEAE) was defined as any event not present before exposure to vaccine or any event already present that worsens in intensity or frequency after exposure. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsens from baseline and is considered clinically significant in the medical and scientific judgment of the Investigator. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study, regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Up to Day 29 (28 days post vaccination)
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Adverse Events (AEs)
ParticipantsmRNA-1273 + PlacebomRNA-1010 + PlacebomRNA-1010 + mRNA-1273Dose A: mRNA-1073 Low Dose + PlaceboDose B: mRNA-1073 Medium Dose + PlaceboDose C: mRNA-1073 High Dose + Placebo
Number of Participants With Unsolicited Adverse Events (AEs)72114191122
PrimaryNumber of Participants With Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), Medically-Attended AEs (MAAEs) and AEs Leading to Discontinuation

An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner. This would include visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or COVID-19 and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Up to Day 181
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), Medically-Attended AEs (MAAEs) and AEs Leading to Discontinuation
ParticipantsmRNA-1273 + PlacebomRNA-1010 + PlacebomRNA-1010 + mRNA-1273Dose A: mRNA-1073 Low Dose + PlaceboDose B: mRNA-1073 Medium Dose + PlaceboDose C: mRNA-1073 High Dose + Placebo
SAEs210010
AESIs020101
MAAEs133832343444
AEs leading to discontinuation000000
SecondaryGeometric Mean Titer of Anti-Hemagglutinin Antibodies at Day 29, as Measured by Hemagglutination Inhibition Assay (HAI) For Vaccine-Matched Seasonal Influenza A and B Strains

Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included BV and BY.

Time frame:
Day 29
Reported as:
Geometric mean · titer
Geometric Mean Titer of Anti-Hemagglutinin Antibodies at Day 29, as Measured by Hemagglutination Inhibition Assay (HAI) For Vaccine-Matched Seasonal Influenza A and B Strains
titermRNA-1010 + PlacebomRNA-1010 + mRNA-1273Dose A: mRNA-1073 Low Dose + PlaceboDose B: mRNA-1073 Medium Dose + PlaceboDose C: mRNA-1073 High Dose + Placebo
Influenza A H1N1 Antibody175.41 (139.67 to 220.30)134.04 (110.72 to 162.26)104.78 (82.94 to 132.39)111.33 (90.94 to 136.29)108.68 (88.64 to 133.26)
Influenza A H3N2 Antibody189.9 (145.67 to 247.54)214.12 (171.36 to 267.56)144.36 (111.87 to 186.29)141.15 (112.68 to 176.80)129.94 (103.77 to 162.715)
Influenza B BV Antibody106.22 (89.66 to 125.83)107.91 (92.79 to 125.50)91.78 (77.16 to 109.16)89.27 (75.92 to 104.98)84.82 (72.56 to 99.15)
Influenza B BY Antibody194.51 (163.21 to 231.81)182.01 (152.26 to 217.58)139.48 (112.70 to 172.61)130.27 (107.67 to 157.61)121.29 (99.73 to 147.52)
SecondaryGeometric Mean Titer of VAC62 Neutralizing Antibody at Day 29, as Measured by Pseudovirus Neutralization Assay (or Binding Antibody Assay) For Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Time frame:
Day 29
Reported as:
Geometric mean · titer
Geometric Mean Titer of VAC62 Neutralizing Antibody at Day 29, as Measured by Pseudovirus Neutralization Assay (or Binding Antibody Assay) For Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
titermRNA-1273 + PlacebomRNA-1010 + mRNA-1273Dose A: mRNA-1073 Low Dose + PlaceboDose B: mRNA-1073 Medium Dose + PlaceboDose C: mRNA-1073 High Dose + Placebo
Geometric Mean Titer of VAC62 Neutralizing Antibody at Day 29, as Measured by Pseudovirus Neutralization Assay (or Binding Antibody Assay) For Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)8477.30 (6424.05 to 11186.62)6075.76 (5119.62 to 7210.47)7573.97 (6475.43 to 8858.86)5678.54 (4671.74 to 6902.32)4410.29 (3762.65 to 5169.41)
SecondaryGeometric Mean Fold Rise of Anti-Hemagglutinin Antibodies at Day 29, as Measured by Hemagglutination Inhibition Assay (HAI) For Vaccine-Matched Seasonal Influenza A and B Strains

Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included BV and BY.

Time frame:
Day 29
Reported as:
Geometric mean · ratio
Geometric Mean Fold Rise of Anti-Hemagglutinin Antibodies at Day 29, as Measured by Hemagglutination Inhibition Assay (HAI) For Vaccine-Matched Seasonal Influenza A and B Strains
ratiomRNA-1010 + PlacebomRNA-1010 + mRNA-1273Dose A: mRNA-1073 Low Dose + PlaceboDose B: mRNA-1073 Medium Dose + PlaceboDose C: mRNA-1073 High Dose + Placebo
Influenza A H1N1 Antibody3.97 (3.19 to 4.95)3.31 (2.76 to 3.96)2.25 (1.89 to 2.68)2.48 (2.06 to 2.98)2.67 (2.21 to 3.23)
Influenza A H3N2 Antibody5.82 (4.56 to 7.43)5.07 (4.19 to 6.14)3.84 (3.22 to 4.58)4.15 (3.33 to 5.18)3.41 (2.80 to 4.14)
Influenza B BV Antibody1.61 (1.42 to 1.82)1.64 (1.47 to 1.84)1.29 (1.14 to 1.44)1.29 (1.18 to 1.43)1.29 (1.16 to 1.43)
Influenza B BY Antibody2.68 (2.25 to 3.19)2.17 (1.85 to 2.53)1.63 (1.46 to 1.83)1.65 (1.46 to 1.87)1.58 (1.41 to 1.78)
SecondaryGeometric Mean Fold Rise of VAC62 Neutralizing Antibody at Day 29, as Measured by Pseudovirus Neutralization Assay (or Binding Antibody Assay) For SARS-CoV-2

The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. 95% CI was calculated based on the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation.

Time frame:
Day 29
Reported as:
Geometric mean · ratio
Geometric Mean Fold Rise of VAC62 Neutralizing Antibody at Day 29, as Measured by Pseudovirus Neutralization Assay (or Binding Antibody Assay) For SARS-CoV-2
ratiomRNA-1273 + PlacebomRNA-1010 + mRNA-1273Dose A: mRNA-1073 Low Dose + PlaceboDose B: mRNA-1073 Medium Dose + PlaceboDose C: mRNA-1073 High Dose + Placebo
Geometric Mean Fold Rise of VAC62 Neutralizing Antibody at Day 29, as Measured by Pseudovirus Neutralization Assay (or Binding Antibody Assay) For SARS-CoV-26.14 (3.98 to 9.48)4.07 (3.26 to 5.07)3.50 (2.76 to 4.44)3.45 (2.82 to 4.22)3.18 (2.73 to 3.69)
SecondaryPercentage of Participants With Seroconversion as Measured by HAI Assay For Vaccine-Matched Seasonal Influenza A and B Strains

Seroconversion at a participant level is defined as a pre-vaccination HAI titer \< 1:10 and a post-vaccination HAI titer \>= 1:40 or a pre-vaccination HAI titer \>= 1:10 and a minimum 4-fold rise in post vaccination HAI antibody titer.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With Seroconversion as Measured by HAI Assay For Vaccine-Matched Seasonal Influenza A and B Strains
percentage of participantsmRNA-1010 + PlacebomRNA-1010 + mRNA-1273Dose A: mRNA-1073 Low Dose + PlaceboDose B: mRNA-1073 Medium Dose + PlaceboDose C: mRNA-1073 High Dose + Placebo
Influenza A H1N1 Antibody47.1 (36.3 to 58.1)42.6 (32.4 to 53.2)27.5 (18.6 to 37.8)31.4 (21.8 to 42.3)31.6 (22.4 to 41.9)
Influenza A H3N2 Antibody64.4 (53.4 to 74.4)63.8 (53.3 to 73.5)53.8 (43.1 to 64.4)53.5 (42.4 to 64.3)42.1 (32.0 to 52.7)
Influenza B BV Antibody16.1 (9.1 to 25.5)9.6 (4.5 to 17.4)3.3 (0.7 to 9.3)2.3 (0.3 to 8.1)6.3 (2.4 to 13.2)
Influenza B BY Antibody32.2 (22.6 to 43.1)19.1 (11.8 to 28.6)11.0 (5.4 to 19.3)10.5 (4.9 to 18.9)10.5 (5.2 to 18.5)
SecondaryPercentage of Participants With Seroresponse as Measured by PsVNA (or Binding Antibody Assay) For SARS-CoV-2

Seroresponse at a participant level is defined as an increase from below the lower limit of quantification (LLOQ) to \>= 4 x LLOQ if baseline neutralizing antibody (nAb) level is \< LLOQ, or \>= 4 fold rise if baseline nAb level is \>=LLOQ.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With Seroresponse as Measured by PsVNA (or Binding Antibody Assay) For SARS-CoV-2
percentage of participantsmRNA-1273 + PlacebomRNA-1010 + mRNA-1273Dose A: mRNA-1073 Low Dose + PlaceboDose B: mRNA-1073 Medium Dose + PlaceboDose C: mRNA-1073 High Dose + Placebo
Percentage of Participants With Seroresponse as Measured by PsVNA (or Binding Antibody Assay) For SARS-CoV-252.4 (36.4 to 68.0)44.4 (34.0 to 55.3)37.5 (27.4 to 48.5)36.5 (26.3 to 47.6)35.9 (26.1 to 46.5)

Adverse events

Collected over Day 1 through Day 181. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
mRNA-1273 + Placebo0/49 (0%)2/49 (4.1%)42/49 (85.7%)
mRNA-1010 + Placebo0/99 (0%)1/99 (1%)86/99 (86.9%)
mRNA-1010 + mRNA-12730/101 (0%)0/101 (0%)93/101 (92.1%)
Dose A: mRNA-1073 Low Dose + Placebo0/100 (0%)0/100 (0%)94/100 (94%)
Dose B: mRNA-1073 Medium Dose + Placebo0/98 (0%)1/98 (1%)81/98 (82.7%)
Dose C: mRNA-1073 High Dose + Placebo0/100 (0%)0/100 (0%)89/100 (89%)
Most frequent serious events
Most frequent serious events
EventmRNA-1273 + PlacebomRNA-1010 + PlacebomRNA-1010 + mRNA-1273Dose A: mRNA-1073 Low Dose + PlaceboDose B: mRNA-1073 Medium Dose + PlaceboDose C: mRNA-1073 High Dose + Placebo
Cardiac failure congestiveCardiac disorders1/490/990/1010/1000/980/100
Urinary tract infectionInfections and infestations1/490/990/1010/1000/980/100
Septic shockInfections and infestations0/490/990/1010/1001/980/100
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/490/990/1010/1001/980/100
Tibia fractureInjury, poisoning and procedural complications0/491/990/1010/1000/980/100
Most frequent other events
Showing 10 of 14
Most frequent other events
EventmRNA-1273 + PlacebomRNA-1010 + PlacebomRNA-1010 + mRNA-1273Dose A: mRNA-1073 Low Dose + PlaceboDose B: mRNA-1073 Medium Dose + PlaceboDose C: mRNA-1073 High Dose + Placebo
Injection site painGeneral disorders38/4980/9989/10191/10076/9878/100
FatigueGeneral disorders25/4957/9979/10167/10045/9851/100
MyalgiaMusculoskeletal and connective tissue disorders20/4952/9973/10159/10042/9841/100
HeadacheNervous system disorders18/4941/9964/10163/10042/9845/100
ChillsGeneral disorders10/4931/9951/10146/10030/9820/100
ArthralgiaMusculoskeletal and connective tissue disorders17/4930/9949/10149/10035/9831/100
Injection site lymphadenopathyGeneral disorders15/4919/9925/10126/10020/9822/100
VomitingGastrointestinal disorders7/4914/9923/10114/10014/986/100
PyrexiaGeneral disorders2/494/9920/10117/1005/982/100
COVID-19Infections and infestations3/4914/9911/10113/10013/9818/100

Baseline characteristics

The Full analysis set consisted of all randomly assigned participants who received the investigational product (IP). Participants were analyzed according to the group to which they were randomized.

Age, Continuous
Age, Continuous(years)mRNA-1273 + PlacebomRNA-1010 + PlacebomRNA-1010 + mRNA-1273Dose A: mRNA-1073 Low Dose + PlaceboDose B: mRNA-1073 Medium Dose + PlaceboDose C: mRNA-1073 High Dose + PlaceboTotal
Mean47.8 ± 15.3747.4 ± 14.4948.5 ± 14.5549.3 ± 15.1049.0 ± 13.9348.2 ± 14.5448.4 ± 14.55
Sex: Female, Male
Sex: Female, Male(Participants)mRNA-1273 + PlacebomRNA-1010 + PlacebomRNA-1010 + mRNA-1273Dose A: mRNA-1073 Low Dose + PlaceboDose B: mRNA-1073 Medium Dose + PlaceboDose C: mRNA-1073 High Dose + PlaceboTotal
Female295465555664323
Male204536454236224
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)mRNA-1273 + PlacebomRNA-1010 + PlacebomRNA-1010 + mRNA-1273Dose A: mRNA-1073 Low Dose + PlaceboDose B: mRNA-1073 Medium Dose + PlaceboDose C: mRNA-1073 High Dose + PlaceboTotal
Hispanic or Latino31114118754
Not Hispanic or Latino428885888892483
Unknown or Not Reported40212110
Race (NIH/OMB)
Race (NIH/OMB)(Participants)mRNA-1273 + PlacebomRNA-1010 + PlacebomRNA-1010 + mRNA-1273Dose A: mRNA-1073 Low Dose + PlaceboDose B: mRNA-1073 Medium Dose + PlaceboDose C: mRNA-1073 High Dose + PlaceboTotal
American Indian or Alaska Native0110103
Asian02534317
Native Hawaiian or Other Pacific Islander0001001
Black or African American1113817161378
White378385797683443
More than one race0020103
Unknown or Not Reported1000012
08

Study locations

14 sites
  • Research Centers of America
    Hollywood, Florida 33024, United States
  • AES - DRS - Optimal Research Illinois - Peoria
    Peoria, Illinois 61614, United States
  • Meridian
    Sioux City, Iowa 51106, United States
  • Benchmark Research
    Metairie, Louisiana 70006, United States
  • Meridian
    Norfolk, Nebraska 68701, United States
  • Meridian
    Binghamton, New York 13901, United States
  • Rochester Clinical Research Inc
    Rochester, New York 14609, United States
  • Meridian
    Cincinnati, Ohio 45219, United States
  • Meridian
    Cincinnati, Ohio 45246, United States
  • Benchmark Research
    Austin, Texas 78705, United States
  • Benchmark Research
    Fort Worth, Texas 76135, United States
  • DM Clinical Research - CyFair
    Houston, Texas 77065, United States
  • DM Clinical Research - TCDD
    Houston, Texas 77081, United States
  • J Lewis Research
    Salt Lake City, Utah 84121, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Dec 2022, 7 months.

Results were first posted in Feb 2024, 1 year 1 month after primary completion.

Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 7 months is below that.

Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2022
First posted
May 17, 2022
StartActual
May 13, 2022
Primary completionActual
Dec 29, 2022
CompletionActual
Dec 29, 2022
Results first posted
Feb 28, 2024
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05375838
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
May 17, 2022
Start date
May 13, 2022
Primary completion
Dec 29, 2022
Completion
Dec 29, 2022
Results posted
Feb 28, 2024
Last update
Feb 28, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: mRNA-1010 influenza vaccine · 2019-nCoV Vaccine mRNA-1273

Start the discussion